These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9834202

  • 1. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
    Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
    Blood; 1998 Dec 01; 92(11):4003-12. PubMed ID: 9834202
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
    Mitani K.
    Oncogene; 2004 May 24; 23(24):4263-9. PubMed ID: 15156182
    [Abstract] [Full Text] [Related]

  • 5. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
    Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H.
    EMBO J; 1994 Feb 01; 13(3):504-10. PubMed ID: 8313895
    [Abstract] [Full Text] [Related]

  • 6. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, Yazaki Y, Hirai H.
    Blood; 1998 Mar 01; 91(5):1688-99. PubMed ID: 9473235
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular mechanism of blastic crisis in chronic myelocytic leukemia.
    Mitani K.
    Leukemia; 1997 Apr 01; 11 Suppl 3():503-5. PubMed ID: 9209439
    [Abstract] [Full Text] [Related]

  • 11. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G.
    Proc Natl Acad Sci U S A; 1996 Feb 20; 93(4):1642-7. PubMed ID: 8643684
    [Abstract] [Full Text] [Related]

  • 12. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C, Rowley JD, Nucifora G.
    Leukemia; 1997 Apr 20; 11 Suppl 3():273-8. PubMed ID: 9209363
    [Abstract] [Full Text] [Related]

  • 13. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
    Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G.
    Proc Natl Acad Sci U S A; 1996 Feb 06; 93(3):1044-8. PubMed ID: 8577711
    [Abstract] [Full Text] [Related]

  • 14. Oncogenic mechanisms of Evi-1 protein.
    Hirai H, Izutsu K, Kurokawa M, Mitani K.
    Cancer Chemother Pharmacol; 2001 Aug 06; 48 Suppl 1():S35-40. PubMed ID: 11587364
    [Abstract] [Full Text] [Related]

  • 15. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling.
    Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H.
    Blood; 2001 May 01; 97(9):2815-22. PubMed ID: 11313276
    [Abstract] [Full Text] [Related]

  • 16. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
    Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H.
    Nature; 1998 Jul 02; 394(6688):92-6. PubMed ID: 9665135
    [Abstract] [Full Text] [Related]

  • 17. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
    Liu XP, Zhang MR, Dai Y, Zhang L, Li R, Hao YS, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2006 May 02; 27(5):310-3. PubMed ID: 16875579
    [Abstract] [Full Text] [Related]

  • 18. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
    Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN, Rowley JD.
    Proc Natl Acad Sci U S A; 1994 Apr 26; 91(9):4004-8. PubMed ID: 8171026
    [Abstract] [Full Text] [Related]

  • 19. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F, Pisegna S, Diverio D.
    Haematologica; 1997 Apr 26; 82(3):364-70. PubMed ID: 9234595
    [Abstract] [Full Text] [Related]

  • 20. Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1.
    Alliston T, Ko TC, Cao Y, Liang YY, Feng XH, Chang C, Derynck R.
    J Biol Chem; 2005 Jun 24; 280(25):24227-37. PubMed ID: 15849193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.